 Julie Goddard
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Free Tissue Flaps | 4 | 2023 | 33 | 1.150 |
Why?
| | Head and Neck Neoplasms | 7 | 2023 | 471 | 1.150 |
Why?
| | Otolaryngologists | 1 | 2018 | 13 | 0.660 |
Why?
| | Microsurgery | 1 | 2018 | 64 | 0.630 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2019 | 610 | 0.610 |
Why?
| | Parotid Gland | 1 | 2017 | 25 | 0.610 |
Why?
| | Parotitis | 1 | 2017 | 8 | 0.610 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 100 | 0.580 |
Why?
| | Vascular Malformations | 1 | 2017 | 47 | 0.570 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 251 | 0.510 |
Why?
| | Lymph Node Excision | 2 | 2019 | 158 | 0.460 |
Why?
| | Thyroidectomy | 1 | 2013 | 54 | 0.450 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2020 | 900 | 0.450 |
Why?
| | Carcinoma | 1 | 2013 | 204 | 0.400 |
Why?
| | Thyroid Neoplasms | 1 | 2013 | 278 | 0.360 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1200 | 0.360 |
Why?
| | Eyelids | 1 | 2022 | 26 | 0.210 |
Why?
| | Orbit | 1 | 2022 | 59 | 0.210 |
Why?
| | Laryngectomy | 2 | 2018 | 19 | 0.200 |
Why?
| | Margins of Excision | 2 | 2018 | 31 | 0.200 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 307 | 0.190 |
Why?
| | Oropharynx | 1 | 2020 | 41 | 0.190 |
Why?
| | Mouth | 1 | 2020 | 74 | 0.190 |
Why?
| | Laryngeal Neoplasms | 2 | 2020 | 39 | 0.190 |
Why?
| | Larynx | 1 | 2020 | 55 | 0.180 |
Why?
| | Survival Rate | 3 | 2019 | 1720 | 0.180 |
Why?
| | Radiosurgery | 1 | 2022 | 318 | 0.170 |
Why?
| | Reoperation | 2 | 2018 | 557 | 0.170 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 12 | 0.170 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 265 | 0.170 |
Why?
| | Pharyngectomy | 1 | 2018 | 2 | 0.170 |
Why?
| | Lymph Nodes | 2 | 2019 | 455 | 0.170 |
Why?
| | Medicare | 2 | 2020 | 665 | 0.170 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 79 | 0.160 |
Why?
| | Nomograms | 1 | 2018 | 48 | 0.160 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2018 | 51 | 0.160 |
Why?
| | Canada | 1 | 2018 | 340 | 0.150 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 10 | 0.150 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 16 | 0.150 |
Why?
| | Parotid Diseases | 1 | 2017 | 5 | 0.150 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 19 | 0.150 |
Why?
| | Surgical Flaps | 1 | 2018 | 118 | 0.150 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 18 | 0.150 |
Why?
| | Nose Neoplasms | 1 | 2017 | 21 | 0.150 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 254 | 0.150 |
Why?
| | Parotid Neoplasms | 1 | 2017 | 16 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 59 | 0.150 |
Why?
| | Microvessels | 1 | 2017 | 77 | 0.150 |
Why?
| | Vocal Cord Dysfunction | 1 | 2016 | 9 | 0.140 |
Why?
| | Humans | 20 | 2023 | 119032 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2018 | 250 | 0.130 |
Why?
| | Tomography, Optical Coherence | 1 | 2016 | 126 | 0.130 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 693 | 0.120 |
Why?
| | Recurrence | 1 | 2017 | 975 | 0.120 |
Why?
| | Postoperative Complications | 3 | 2023 | 2235 | 0.120 |
Why?
| | Female | 11 | 2019 | 61588 | 0.120 |
Why?
| | Male | 12 | 2022 | 57818 | 0.110 |
Why?
| | Middle Aged | 9 | 2020 | 27627 | 0.110 |
Why?
| | Aged | 10 | 2020 | 19661 | 0.110 |
Why?
| | Ultrasonography | 1 | 2017 | 716 | 0.110 |
Why?
| | United States | 5 | 2020 | 12557 | 0.110 |
Why?
| | Disease-Free Survival | 3 | 2020 | 649 | 0.110 |
Why?
| | Adult | 8 | 2022 | 31525 | 0.100 |
Why?
| | Melanoma | 1 | 2017 | 664 | 0.090 |
Why?
| | Retrospective Studies | 7 | 2023 | 12990 | 0.090 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1223 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3175 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 667 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1390 | 0.080 |
Why?
| | Databases, Factual | 3 | 2019 | 1231 | 0.080 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 333 | 0.080 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4552 | 0.080 |
Why?
| | Anion Transport Proteins | 1 | 2006 | 12 | 0.070 |
Why?
| | Directed Molecular Evolution | 1 | 2006 | 25 | 0.070 |
Why?
| | Time Factors | 1 | 2017 | 6414 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4709 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2017 | 189 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 360 | 0.070 |
Why?
| | Alphapapillomavirus | 2 | 2018 | 38 | 0.070 |
Why?
| | Prognosis | 3 | 2019 | 3443 | 0.070 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1167 | 0.060 |
Why?
| | Survival Analysis | 2 | 2019 | 1267 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1125 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1474 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2006 | 454 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2023 | 146 | 0.050 |
Why?
| | Optic Nerve | 1 | 2022 | 65 | 0.050 |
Why?
| | Injections | 1 | 2022 | 167 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 230 | 0.050 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 230 | 0.050 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 237 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2020 | 131 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 298 | 0.040 |
Why?
| | Hypopharynx | 1 | 2018 | 2 | 0.040 |
Why?
| | Anticoagulants | 1 | 2023 | 559 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 114 | 0.040 |
Why?
| | Preoperative Period | 1 | 2018 | 110 | 0.040 |
Why?
| | Critical Care | 1 | 2022 | 493 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 309 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6562 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 43 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 42 | 0.040 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 39 | 0.040 |
Why?
| | Biopsy, Fine-Needle | 1 | 2017 | 69 | 0.040 |
Why?
| | Office Visits | 1 | 2017 | 83 | 0.040 |
Why?
| | Vocal Cords | 1 | 2016 | 30 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 242 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 200 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 462 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 271 | 0.030 |
Why?
| | Laryngoscopy | 1 | 2016 | 97 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2020 | 496 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 963 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1129 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 842 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 845 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1295 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9346 | 0.030 |
Why?
| | Length of Stay | 1 | 2018 | 1031 | 0.030 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 14 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 28 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 65 | 0.030 |
Why?
| | Cetuximab | 1 | 2013 | 99 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 343 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 963 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2013 | 740 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1195 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4596 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2013 | 569 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 588 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1691 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3057 | 0.020 |
Why?
| | Renilla | 1 | 2006 | 2 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2436 | 0.020 |
Why?
| | Organic Anion Transporters | 1 | 2006 | 19 | 0.020 |
Why?
| | Gerbillinae | 1 | 2006 | 63 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 5117 | 0.020 |
Why?
| | Protein Interaction Mapping | 1 | 2006 | 104 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2017 | 5256 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 338 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2006 | 522 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 9003 | 0.020 |
Why?
| | Infant | 1 | 2017 | 8295 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 9493 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2073 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2873 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 10799 | 0.010 |
Why?
| | Cell Line | 1 | 2006 | 2707 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 18483 | 0.010 |
Why?
| | Animals | 2 | 2013 | 33399 | 0.010 |
Why?
| | Child | 1 | 2017 | 19137 | 0.010 |
Why?
| | Mice | 1 | 2013 | 15528 | 0.010 |
Why?
|
|
Goddard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|